THE INTERSECTION OF BRAIN SCIENCE & HUMAN POTENTIALPartner with us
neurofeedback.com
The newsletter
← Research & Evidence
MixedRegistered single-blind sham lead-in trial with randomized active-treatment target

Repetitive transcranial magnetic stimulation to the right dorsomedial prefrontal cortex and dorsolateral prefrontal cortex for treatment of post-traumatic stress disorder: A sham lead-in randomized controlled trial

Published November 17, 2026. In this 25-person PTSD study, clinician-rated symptoms improved substantially during five sham sessions. Symptoms improved further when both active-target groups were combined, but the comparison between the sham-phase change and active-phase change was not statistically significant, and neither active target was better than the other. The study does not establish that active rTMS added benefit beyond the initial sham response.

Campbell C, Wilson AJ, Tabor JB, et al.
Canadian Journal of Psychiatry · Publication date: 2026-11-17
Added to site: 2026-11-21
DOI: 10.1177/07067437261505218

Published online November 17, 2026. Added to Neurofeedback.com November 21, 2026 after comparison with fresh and retained candidates. The source publication date is separate from the site addition date.

Modalities
Repetitive transcranial magnetic stimulation, Low-frequency rTMS, Noninvasive brain stimulation
Clinical focus
Post-traumatic stress disorder, Sham response, DLPFC and DMPFC targeting
Population
Twenty-five adults ages 18 to 65 with clinician-diagnosed PTSD, adult trauma at least six months earlier and no previous rTMS
Sample
25 randomized to right DLPFC, n=14, or right DMPFC, n=11; two were excluded from later analyses because of location discomfort and one stopped after three active sessions
Intervention / method
All participants received five daily sham sessions followed by 20 daily active sessions at 1 Hz, 1,500 pulses and 100% to 120% of resting motor threshold. The primary outcome was the clinician-rated CAPS-5. The registered trial was NCT03840369.
Comparator
Within-subject sham lead-in followed by active rTMS, with randomized comparison of right DLPFC versus right DMPFC during the active phase; there was no concurrent sham arm during active treatment

Clinician summary

CAPS-5 improved by 12.8 points from baseline to post-sham, 95% CI -17.0 to -8.7, p<.001. The combined post-sham to post-rTMS change was -5.8, 95% CI -10.5 to -1.13, p=.015, but the difference-in-differences comparison was not significant, 7.0, 95% CI -0.59 to 14.6, p=.071. There was no significant CAPS-5 time-by-target interaction or DLPFC-versus-DMPFC advantage. Two participants could not tolerate targeting close enough to the specified coordinates, one stopped after worsening mental health judged unrelated, and transient headache was reported by nine during sham and eleven during active treatment.

How to interpret the findings

The trial recruited 25 people rather than the planned approximately 40 per group. There was no concurrent true sham group during the active phase, sham lasted one week while active treatment lasted four weeks, study personnel were not blinded, attrition occurred and COVID-19 interrupted recruitment. The sequence cannot cleanly separate active treatment from time, expectancy, repeated contact, regression or other nonspecific effects. The results do not establish clinical efficacy, an optimal target or comparative effectiveness for PTSD.

Equipment and disclosures

The source names Magstim and MagVenture stimulators and Brainsight and Visor2 neuronavigation as protocol details. It does not establish superiority for a device or commercial system, and no equipment is attributed to BrainMaster or another site sponsor.

The authors reported no potential conflicts. The study was funded by the Department of National Defence, Canada, through the Innovation for Defence Excellence and Security program, grant IDEaS_CP-0316. No correction, retraction or expression-of-concern notice tied to the DOI appeared in the checked PubMed, publisher, registry or bounded DOI and title searches on November 21, 2026; this is not assurance of absence. AI-assisted source review for Neurofeedback.com, not independent human clinical review.

Related evidence

Compare findings from the same clinical area, including mixed results.

Full text checked · Checked 2026-11-21

Summary prepared with AI assistance. Source verification does not imply an independent replication or a clinician's endorsement. Read our review method.